PD-L1 protein as assessed by immunohistochemistry has been shown to positively correlate with response to PD-1 targeting therapy in several studies on melanoma, lung cancer, and other tumor entities, thus making this parameter a potential predictive biomarker [22, 23, 24, 25]. The gene discussed is PDCD1; the disease is lung carcinoma.